-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shufang (Shanghai) Pharmaceutical, a subsidiary of Shufang Pharmaceutical, and Shanghai Heyu Biopharmaceutical have reached an exclusive licensing agreement to jointly develop the innovative drug ABSK021 for the application of indications in the field of rare diseases of the nervous system in the Greater China region
According to the exclusive license agreement, Sufang Pharmaceutical will obtain the exclusive rights to develop, produce, and commercialize ABSK021 in Mainland China, Hong Kong and Macau Special Administrative Regions (hereinafter collectively referred to as the "authorized regions").
Note: The original text has been deleted